TABLE 4.
Activity of methylenecyclopropane analogues against HSV-1 and -2 in HFF
| Drug | EC50 (μM) for virus determined by method
|
|||
|---|---|---|---|---|
| HSV-1
|
HSV-2
|
|||
| CPE inhibition | PR | CPE inhibition | PR | |
| ACV | 3.1 | 4.3 | 6.3 | 4.3 |
| QYL-284A | 0.14 | 140 | 10.6 | 47.9 |
| QYL-438 | 61.7 | NTa | 429 | NT |
| QYL-468 | >104 | NT | >104 | NT |
| QYL-546 | 413 | NT | >430 | NT |
| QYL-587A | >460 | NT | >430 | NT |
| QYL-678 | 20.2 | 22.1 | 181 | 39.2 |
| QYL-685 | 2.7 | 5.5 | 21.5 | 12.7 |
| QYL-769 | >73.4 | NT | >73.4 | NT |
| QYL-418 | >76.4 | NT | >76.4 | NT |
| QYL-972 | 0.78 | 1.1 | 0.76 | 0.88 |
| QYL-941 | 343 | NT | 364 | NT |
| QYL-975 | 1.3 | 0.8 | 2.5 | 0.8 |
a
NT, not tested.